Thursday, May 29, 2014
Epithelial cancers are the most common malignancies, but
immunotherapy development has been stymied because of the difficulty in
identifying targets that are not expressed on normal tissues. A National Cancer Institute
team has now used a next-generation sequencing approach to identify such rare
mutations in one patient and determine which, if any, are recognized by the
immune system. The team then developed an autologous cell therapy against one
of the mutations that led to cancer regression and disease stabilization.1
Rosenberg cautioned that much more work is needed to turn
the method into a therapy suitable for widespread use.
Baas, T. SciBX 7(21); doi:10.1038/scibx.2014.602
Published online May 29, 2014
1. Tran, E. et al.
Science; published online May 9, 2014; doi:10.1126/science.1251102
Contact: Steven A. Rosenberg, National Cancer Institute, Bethesda, Md.
AND INSTITUTIONS MENTIONED
George Washington University School of Medicine and Health
Sciences, Washington, D.C.
Juno Therapeutics Inc., Seattle, Wash.
Memorial Sloan Kettering Cancer Center, New York, N.Y.
National Cancer Institute, Bethesda, Md.
Uniformed Services University of the Health Sciences, Bethesda, Md.